the aid library

LIST OPTIONS

Filter

2182

Sort by:

Direction:

Download (40)

View PDF (33)

WHO training package on environmental cleaning: Evaluation methodology guide

World Health Organization WHO (2024) C_WHO

This purpose of this guide is to inform robust evaluations of the WHO training package – a package aimed at personnel whose primary role in health-care facilities is environmental cleaning, hereafter referred to as cleaners. The WHO training package – Environmental cleaning and infection prev... more

Download (160)

View PDF (248)

Laboratory testing for the monkeypox virus
recommended

World Health Organization (WHO) (2022) C_WHO

Any individual that meets the suspected case definition of monkeypox should be offered testing in appropriately equipped laboratories by staff trained in the relevant technical and safety procedures. Confirmation of monkeypox virus infection is based on nucleic acid amplification testing (NAAT), usi... more

Download (137)

View PDF (145)

Tuberculosis in the WHO African Region: 2023 progress update - September 2023

World Health Organisation (WHO) (2023) C_WHO

This brief update on tuberculosis (TB) in the African region covers the state of TB in the WHO African region, strategic priorities and targets and the impact of COVID-19 on essential services. This is followed by key figures for the region, the role of WHO in country support and, recognizing the im... more

Download (149)

View PDF (216)

COVID-19 natural immunity

World Health Organization WHO (2021) C_WHO

10 May 2021 This scientific brief replaces the WHO Scientific Brief entitled “’Immunity passports’ in the context of COVID-19”, published 24 April 2020. This update is focused on what is currently understood about SARS-CoV-2 immunity from natural infection. More information about considera... more

Download (272)

View PDF (366)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (406)

View PDF (421)

Global Strategy for dengue prevention and control, 2012–2020

R. Velayudhan World Health Organization WHO (2012) C_WHO

During the past ﬁve decades, the incidence of dengue has increased 30-fold. Some 50–100 million new infections are estimated to occur annually in more than 100 endemic countries, with a documented further spread to previously unaffected areas; every year hundreds of thousands of severe cases ari... more

Download (1202)

View PDF (3741)

WHEELCHAIR SERVICE TRAINING PACKAGE Reference Manual for Participants (Intermediate level)

Sarah Frost, Kylie Mines, Jamie Noon, Elsje Scheffler, and Rebecca Jackson Stoeckle WHO; USAID (2013) C_WHO

Following the release of the Wheelchair Service Training Package – Basic level (WSTP-B), WHO in partnership with United States Agency for International Development (USAID) has developed the Wheelchair Service Training Package – Intermediate Level (WSTP-I). WSTP-I is the second part of the WHO w... more

Download (166)

View PDF (181)

Social Stigma associated with COVID-19
recommended

World Health Organization (WHO); UNICEF; IFRC (2020) C_WHO

A guide to preventing and addressing social stigma. Social stigma in the context of health is the negative association between a person or group of people who share certain characteristics and a specific disease. In an outbreak, this may mean people are labelled, stereotyped, discriminated against,... more

Download (646)

View PDF (2505)

The Health Literacy Toolkit For Low- and Middle-Income Countries

Sarity Dodson, Suvajee Good and Richard Osborne World Health Organization - Regional Office South-East Asia (2015)

A series of information sheets to help empower communities and strengthen health systems This series of information sheets introduces health literacy, its relevance to public policy, and the ways it can be used to inform the promotion of good health, the prevention and management of communicab... more

Download (124)

View PDF (366)

Financing HIV Programming: How Much Should Low And Middle-Income Countries and their Donors Pay?

Galarraga, O.; V. J. Wirtz; Y. Santa-Ana-Tellez et al. PLOS One (2013) C1

Global HIV control funding falls short of need. To maximize health outcomes, it is critical that national governments sustain reasonable commitments, and that international donor assistance be distributed according to country needs and funding gaps. We develop a country classification framework in t... more

Download (99)

View PDF (130)

COVID-19 in Yemen: preparedness measures in a fragile state

Dureab, F.; S. Al-Awlaqi and A.Jahn The Lancet (2020) CC

The Lancet DOI: 10.1016/S2468-2667(20)30101-8 WHO declared COVID-19 to be a pandemic on March 11, 2020. The pandemic eventually reached Yemen, with the first laboratory confirmed case announced on April 10. emen has structural vulnerabilities that have developed over a protracted period of conflic... more

Download (33)

View PDF (28)

2023 حالة أطفال العالم لعام

UN Children's Fund UNICEF (2024) CC

The article focuses on "The State of the World’s Children 2023" report published by UNICEF. It highlights the critical role of vaccines in saving lives and the challenges in global immunization efforts, especially for marginalized and underserved children. The report emphasizes the impact of COVID... more

Download (250)

View PDF (327)

Key political commitment documents for tuberculosis prevention and care and their intended influence in the WHO European Region

World Health Organization WHO, Regional Office for Europe (2019) C_WHO

This analytical report reviews and discusses the potential role and influence of political commitment in implementing endorsements and conducting policy in the field of tuberculosis (TB) prevention and care. It promotes discussion by comparing and analysing the extent to which selected international... more

Download (1044)

View PDF (2161)

Community dialogues for healthy children: encouraging communities to talk

Malaria Consortium (2014)

Integrated community case management (ICCM) – an approach where community-based health workers are trained to identify, treat and refer children under-five with pneumonia, diarrhoea and malaria – is increasingly being used across sub-Saharan Africa to supplement the gaps in basic healthcare prov... more

Download (155)

View PDF (207)

WHO position paper on hepatitis A vaccines – October 2022

Pan American Health Organization PAHO ; World Health Organization WHO (2022) C_WHO

The position papers are intended for use by national public health officials and managers of immunization programmes. They may also be of interest to international funding agencies, vaccine advisory groups, vaccine manufacturers, health professionals, researchers, the scientific media and the genera... more

Download (503)

View PDF (897)

Improving medicines access and use for child health: a guide to developing interventions

Ross-Degnan, D., Vialle-Valentin, C., and Briggs, J. USAID, SIAPS (Systems for Improved Access to Pharmaceuticals and Services) (2015) C1

Submitted to the US Agency for International Development by the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program. This manual provides a framework to identify problems and design interventions to improve access to and use of medicines for children. It is a resource for ... more

Download (312)

View PDF (336)

Healthier, fairer, safer: the global health journey 2007–2017

Donaldson, Liam World Health Organization (WHO) (2017) C_WHO

The report reflects on the trends, achievements and challenges in global health over the past decade during which Dr Margaret Chan has been Director-General of WHO. It discusses the role of WHO in dealing with such issues as the rise of noncommunicable diseases, leaps in life expectancy, and emergin... more

Download (123)

View PDF (179)

Paediatric Oncology Nursing Care in low- and middle-income countries: a need for baseline standards

Day S., Challinor J., Hollis R., et al. (2015) CC

This article looks at the Baseline Standards developed by the International Society for Paediatric Oncology (SIOP) for paediatric oncology nursing care in low- and middle-income countries. The Baseline Standards lay the foundation for effective care and address barriers such as inadequate staffin... more

Download (2182)

View PDF (6545)

WHO Model Formulary for Children
recommended

World Health Organization WHO (2010) C_WHO

WHO Model Formulary for children based on the Second Model List of Essential Medicines for Children 2009. In 2007, the World Health Assembly passed a Resolution titled ‘Better Medicines for Children’. This resolution recognized the need for research and development into medicines for children,... more

Download (908)

View PDF (820)

Building Bridges

E. Toska, et al. Comic Relief; Health Poverty Action (2013) CC

Lessons and best practices in empowering pastoralist communities to prevent HIV infection and reduce the impact of AIDS in Ethiopia. Briefing Paper

Laboratory testing for the monkeypox virus recommended

Social Stigma associated with COVID-19 recommended

WHO Model Formulary for Children recommended

Laboratory testing for the monkeypox virus
recommended

Social Stigma associated with COVID-19
recommended

WHO Model Formulary for Children
recommended